#68 - Sally Ann Reiss - Founder and CEO of PlayyOn

SallyAnn Reiss is the founder and CEO of PlayyOn, an online platform for managing amateur sports and recreation. Playyon provides a suite of online solutions for the 1.5 million organized programs in North America, serving over 100 million athletes. PlayyOn’s total addressable market is $17 billion and includes sports such as basketball, baseball, football, soccer, cheer, chess, robotics, sailing and more.

Sally Ann developed her leadership skills on the founding of 5 successful startups, with key roles in operations, finance, and project management.  She started her career at TiVo, the pioneering digital video recording company that went public in 1999 and was acquired for $1.1 billion by Rovi in 2016. SallyAnn later was on the team that built Bina Technologies, a genomics software innovator subsequently acquired by Roche for an estimated $500 million in 2014. She also helped launch three healthcare startups before founding PlayyOn.

SallyAnn is a passionate advocate for healthier communities - and not just on the playing field. In 2003 she co-founded the organization today known as Summit Preparatory School. Originally a single college preparatory campus aimed at widening access to higher education, Summit today is a thriving charter school franchise with 13 in California and Washington state.

Born in British Columbia, Canada, SallyAnn earned her Bachelor of Arts in Economics and Political Science from the University of Victoria. She is an avid sports enthusiast and plays basketball, soccer, tennis, softball, golf and pickleball in addition to scuba diving and horseback riding. Her family includes three adult children, a wonderful husband, and many pets.

Founding Team Executive Management: 

TiVo:  Founded in 1997, is a digital video recording software and service company. In 1999, the company raised $88 million on 5.5m shares through an IPO, at $16 per share. Tivo was acquired for $1.1 Billion by Rovi in 2016.

Bina Technologies:  A super-computing software for genomics raised $10M then was acquired by Roche in 2014 for an estimated $500 million.

Organ-i: produced a Kidney Solid Organ Rejection Test (k-SORT) raised $250K and then sold its technology to Immucor for $12 million.

IL-2 Rx: In 2018, an autoimmune drug spun out of Stanford University. Funded by private investors. Potential target for technology acquisition by Gilead and the likes.  Currently technology is still in development.

Omniox: is a biotechnology company, which spun out of Berkeley in 2006 and began to commercialize technologies used in identifying and treating cancer, cardiovascular disease and trauma. As of 2018, the company had raised $20M in venture funding and grants. Currently technology is still in development.

-----

Connect with me on LinkedIn: https://www.linkedin.com/in/andrewghaines/

Subscribe to us on Youtube: https://www.youtube.com/channel/UCJ7cqGc9pC4L1gRaM04ViVw

-----

Thank you to our sponsors for making the Andrew Haines Show possible:

Eggheadcreativestudio.com

livesourceapp.com